

# Xueting Yao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7958587/publications.pdf>

Version: 2024-02-01

12  
papers

56  
citations

1683354

5  
h-index

1719596

7  
g-index

13  
all docs

13  
docs citations

13  
times ranked

76  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BlyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105704.	1.9	6
2	Application of LC-MS/MS method for determination of dihydroartemisin in human plasma in a pharmacokinetic study. <i>Bioanalysis</i> , 2020, 12, 1635-1646.	0.6	0
3	Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 147, 105281.	1.9	9
4	A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 136, 104942.	1.9	7
5	Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 2019, 39, 643-651.	1.1	9
6	A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 20-29.	1.4	1
7	Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide. <i>Biomedical Chromatography</i> , 2019, 33, e4420.	0.8	6
8	Simultaneous determination of TPN729 and its five metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 91-105.	1.4	1
9	Development of an HPLC-MS/MS method to determine janagliflozin in human plasma and urine: application in clinical study. <i>Bioanalysis</i> , 2018, 10, 1439-1454.	0.6	6
10	Metabolites characterization of a novel DPP-4 inhibitor, imigliptin in humans and rats using ultra-high performance liquid chromatography coupled with synapt high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 157, 189-200.	1.4	2
11	A high-performance liquid chromatography-tandem mass spectrometry method for simultaneous determination of imigliptin, its five metabolites and alogliptin in human plasma and urine and its application to a multiple-dose pharmacokinetic study. <i>Biomedical Chromatography</i> , 2018, 32, e4324.	0.8	7
12	Simultaneous determination of imigliptin and its three metabolites in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1002, 300-312.	1.2	2